Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation
Status:
Terminated
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test whether abatacept, a drug approved by the Food and Drug
Administration to treat rheumatoid arthritis, may help blood pressure medications to work
better. This will be studied in people with high blood pressure that is not well controlled
on three or more blood pressure medications, the condition also known as resistant
hypertension. We expect to show that adding abatacept therapy to standardized treatment of
resistant hypertension will result in a greater decrease in blood pressure at 24 weeks
compared to treatment with placebo and conventional blood pressure treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Vanderbilt University Vanderbilt University Medical Center